Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LI-1 Pick a Winner trial in older or unfit AML
ISRCTN40571019Phase 3Completed
- Sponsor
- Cardiff University
- Start
- Apr 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cytarabine, sapacitabine, vosaroxin and quizartinib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (6 arms), sponsored by Cardiff University. Primary endpoints: Overall survival, Complete remission achievement and 4 more. Started Apr 2011; status: completed.
02
Drugs
cytarabinesapacitabinevosaroxinquizartinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN40571019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN40571019.